Page 102 - Genentech News Today

A research team led by University of California, Irvine scientists has developed an innovative method for quickly and efficiently creating vast collections of chemical compounds used in drug discovery by harnessing the power of ribosomes, the molecul

While the company added Kathryn Guarini, PhD and David P. Schenkein, MD to its board, Regeneron announced the departure of Marc Tessier-Lavigne, PhD effective September 1.

Now there are encouraging signs that CLL could join the list of blood cancers that can be effectively treated with CAR T-cell therapy.

Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.

THURSDAY, Sept. 7, 2023 (HealthDay News) -- The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study

Growing interest in AI-powered drug discovery draws some big investors–and regulatory questions

Stephen Hauser, MD, talks about <em>The Face Laughs While the Brain Cries</em>

As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.

A cross-sectional analysis of Medicare Part B data spending shows ophthalmologists who received manufacturer funding were less likely to prescribe bevacizumab.

/PRNewswire/ -- Roots Analysis has announced the addition of "Antibody Drug Conjugate Market (7th Edition), 2023-2035" report to its list of offerings....